uPAR as anti-cancer target: Evaluation of biomarker potential, histological localization, and antibody-based therapy

Current Drug Targets

Volumn 12, Issue 12, 2011, Pages 1744-1760

  Lund, Ida K ^a   Illemann, Martin ^a   Thurison, Tine ^a   Christensen, Ib J ^a   Høyer Hansen, Gunilla ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

Antibody; Biomarker; Cancer; Expression; Localization; Therapy; uPA; uPAR

Indexed keywords

ANTHRAX TOXIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOTOXIN; FRAGILE X MENTAL RETARDATION PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOTOXIN; INHIBITOR PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ATN 658; MONOCLONAL ANTIBODY MU1; P SELECTIN GLYCOPROTEIN LIGAND 1; PROTEIN INHIBITOR; PROUROKINASE; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER LOCALIZATION; CATALYSIS; CELL SURFACE; CELLULAR DISTRIBUTION; CLINICAL EVALUATION; COLORECTAL CANCER; FIBRINOLYSIS; HISTOLOGY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARY CANCER; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; SKIN CANCER; STROMA CELL; TARGET CELL; TRANSGENIC ANIMAL; UPREGULATION; WOUND HEALING;

ANIMALS; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 80054086465     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011797635902     Document Type: Article

References (161)

1. Danø K, Behrendt N, Høyer-Hansen G, et al. Plasminogen activation and cancer. Thromb Haemost 2005; 93: 676-81.
2. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74
3. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57: 25-40.
4. Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost 2005; 93: 627-30.
5. Carmeliet P, Schoonjans L, Kieckens L, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-24.
6. Brownstein C, Deora AB, Jacovina AT, et al. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood 2004; 103: 317-24.
7. Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989; 264: 2185-8.
8. Ellis V, Behrendt N, Danø K. Plasminogen activation by receptor- bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991; 266: 12752-8.
9. Petersen LC, Lund LR, Nielsen LS, Danø K, Skriver L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 1988; 263: 11189-95.
10. Danø K, Rømer J, Nielsen BS, et al. Cancer invasion and tissue remodeling--cooperation of protease systems and cell types. APMIS 1999; 107: 120-7.
11. Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 2010; 120: 3421-31.
12. Croucher DR, Saunders DN, Lobov S, Ranson M. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer 2008; 8: 535-45.
13. Czekay RP, Kuemmel TA, Orlando RA, Farquhar MG. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor- related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol Biol Cell 2001; 12: 1467-79.
14. Nykjær A, Kjøller L, Cohen RL, et al. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J Biol Chem 1994; 269: 25668-76.
15. Olson D, Pöllänen J, Høyer-Hansen G, et al. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 1992; 267: 9129-33.
16. Croucher DR, Saunders DN, Stillfried GE, Ranson M. A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells. Biochem J 2007; 408: 203-10.
17. Duriseti S, Goetz DH, Hostetter DR, Lebeau AM, Wei Y, Craik CS. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. J Biol Chem 2010; 285: 26878-88.
18. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11: 23-36.
19. Zhou HM, Nichols A, Meda P, Vassalli JD. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J 2000; 19: 4817-26.
20. Høyer-Hansen G, Lund IK. Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 2007; 44: 65-102.
21. Høyer-Hansen G, Pessara U, Holm A, et al. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem J 2001; 358: 673-9.
22. Ploug M, Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett 1994; 349: 163-8.
23. Nieves EC, Manchanda N. A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance. J Biol Chem 2010; 285: 12595-603.
24. Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem 2002; 277: 46932-9.
25. Zhu S, Gladson CL, White KE, et al. Urokinase receptor mediates lung fibroblast attachment and migration toward provisional matrix proteins through interaction with multiple integrins. Am J Physiol Lung Cell Mol Physiol 2009; 297: L97-108.
26. Kjøller L, Hall A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol 2001; 152: 1145-57.
27. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9: 794-807.
28. Bugge TH, Suh TT, Flick MJ, et al. The receptor for urokinase- type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 1995; 270: 16886-94.
29. Dewerchin M, Nuffelen AV, Wallays G, et al. Generation and characterization of urokinase receptor-deficient mice. J Clin Invest 1996; 97: 870-8.
30. Rømer J, Bugge TH, Pyke C, et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 1996; 2: 287-92.
31. Lund LR, Green KA, Stoop AA, et al. Plasminogen activation independent of uPA and tPA maintains wound healing in genedeficient mice. EMBO J 2006; 25: 2686-97.
32. Bugge TH, Flick MJ, Danton MJ, et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci U S A 1996; 93: 5899-904.
33. Connolly BM, Choi EY, Gårdsvoll H, et al. Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. Blood 2010; 116: 1593-603.
34. Solberg H, Rinkenberger J, Danø K, Werb Z, Lund LR. A functional overlap of plasminogen and MMPs regulates vascularization during placental development. Development 2003; 130: 4439-50.
35. Green KA, Lund LR. ECM degrading proteases and tissue remodelling in the mammary gland. Bioessays 2005; 27: 894-903.
36. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004; 37: 541-8.
37. Harbeck N, Kates RE, Gauger K, et al. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor- derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 2004; 91: 450-6.
38. Grøndahl-Hansen J, Ralfkiær E, Kirkeby LT, Kristensen P, Lund LR, Danø K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 1991; 138: 111-7.
39. Pyke C, Græm N, Ralfkiær E, et al. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993; 53: 1911-5.
40. Nielsen BS, Sehested M, Duun S, et al. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest 2001; 81: 1485-501.
41. Illemann M, Bird N, Majeed A, et al. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 2009; 124: 1860-70.
42. Rockway TW, Nienaber V, Giranda VL. Inhibitors of the protease domain of urokinase-type plasminogen activator. Curr Pharm Des 2002; 8: 2541-58.
43. Ulisse S, Baldini E, Sorrenti S, D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 2009; 9: 32-71.
44. Hildenbrand R, Allgayer H, Marx A, Stroebel P. Modulators of the urokinase-type plasminogen activation system for cancer. Expert Opin Investig Drugs 2010; 19: 641-52.
45. Janicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20.
46. Look MP, van Putten WLJ, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28.
47. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-66.
48. Thorpe SM. Immunological quantitation of nuclear receptors in human breast cancer: relation to cytosolic estrogen and progesterone receptors. Cancer Res 1987; 47: 1830-5.
49. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-312.
50. Grøndahl-Hansen J, Peters HA, van Putten WL, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995; 1: 1079-87.
51. de Witte JH, Foekens JA, Brünner N, et al. Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer 2001; 85: 85-92.
52. Hildenbrand R, Schaaf A, Dorn-Beineke A, et al. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact. Histol Histopathol 2009; 24: 869-77.
53. Wilhelm OG, Wilhelm S, Escott GM, et al. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol 1999; 180: 225-35.
54. Rønne E, Pappot H, Grøndahl-Hansen J, et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995; 89: 576-81.
55. Riisbro R, Christensen IJ, Piironen T, et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 2002; 8: 1132-41.
56. Grebenchtchikov N, Maguire TM, Riisbro R, et al. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol Rep 2005; 14: 235-9.
57. Salden M, Splinter TA, Peters HA, et al. The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Ann Oncol 2000; 11: 327-32.
58. Pedersen H, Brünner N, Francis D, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-5.
59. Pappot H. The plasminogen activation system in lung cancer--with special reference to the prognostic role in non-small cell lung cancer. APMIS Suppl 1999; 92: 1-29.
60. Piironen T, Laursen B, Pass J, et al. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor. Clin Chem 2004; 50: 2059-68.
61. Høyer-Hansen G, Hamers MJAG, Pedersen AN, et al. Loss of ELISA specificity due to biotinylation of monoclonal antibodies. J Immunol Methods 2000; 235: 91-9.
62. Rønne E, Behrendt N, Ellis V, Ploug M, Danø K, Høyer-Hansen G. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Letters 1991; 288: 233-6.
63. Høyer-Hansen G, Rønne E, Solberg H, et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992; 267: 18224-9.
64. Ploug M, Østergaard S, Gårdsvoll H, et al. Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 2001; 40: 12157-68.
65. Almasi CE, Høyer-Hansen G, Christensen IJ, Danø K, Pappot H. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. Lung Cancer 2005; 48: 349-55.
66. Pappot H, Høyer-Hansen G, Rønne E, et al. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 1997; 33: 867-72.
67. Almasi CE, Høyer-Hansen G, Christensen IJ, Pappot H. Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer. APMIS 2009; 117: 755-61.
68. Meisser A, Cohen M, Bischof P. Concentrations of circulating gelatinases (matrix metalloproteinase-2 and -9) are dependent on the conditions of blood collection. Clin Chem 2005; 51: 274-6.
69. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. J Epidemiol Biostat 2001; 6: 107-38.
70. Henic E, Borgfeldt C, Christensen IJ, Casslén B, Høyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 2008; 14: 5785-93.
71. Drapkin R, Clauss A, Skates S. Urokinase-type plasminogen activator receptor: a beacon of malignancy? Clin Cancer Res 2008; 14: 5643-5.
72. Borgfeldt C, Bendahl PO, Gustavsson B, et al. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer. Int J Cancer 2003; 107: 658-65.
73. Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. Int J Gynecol Cancer 2000; 10: 372-81.
74. Begum FD, Høgdall CK, Kjaer SK, et al. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Anticancer Res 2004; 24: 1981-5.
75. Piironen T, Haese A, Huland H, et al. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 2006; 52: 838-44.
76. Shariat SF, Roehrborn CG, McConnell JD, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007; 25: 349-55.
77. Almasi CE, Brasso K, Iversen P, et al. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. Prostate 2011; 71: 889-907.
78. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994; 344: 401-2.
79. Stephens RW, Nielsen HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 91: 869-74.
80. Nielsen HJ, Christensen IJ, Moesgaard F, Kehlet H. Ranitidine as adjuvant treatment in colorectal cancer. Br J Surg 2002; 89: 1416-22.
81. Lomholt AF, Christensen IJ, Høyer-Hansen G, Nielsen HJ. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol 2010; 49: 805-11.
82. Thurison T, Lomholt AF, Rasch MG, et al. A new assay for measurement of the liberated domain i of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer. Clin Chem 2010; 56: 1636-40.
83. Nielsen HJ, Brünner N, Frederiksen C, et al. Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection. Scand J Gastroenterol 2008; 43: 242-8.
84. Liu D, Aguirre GJ, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002; 1: 445-57.
85. Jo M, Thomas KS, Wu L, Gonias SL. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J Biol Chem 2003; 278: 46692-8.
86. Bifulco K, Longanesi-Cattani I, Gala M, et al. The soluble form of urokinase receptor promotes angiogenesis through its SER(88) - ARG-SER-ARG-TYR(92) chemotactic sequence. J Thromb Haemost 2010; 8: 2789-99.
87. Nikolova DA, Asangani IA, Nelson LD, et al. Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer Res 2009; 69: 2461-70.
88. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-71.
89. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.
90. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
91. Lomholt AF, Høyer-Hansen G, Nielsen HJ, Christensen IJ. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer. Br J Cancer 2009; 101: 992-7.
92. Luther T, Magdolen V, Albrecht S, et al. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Pathol 1997; 150: 1231-44.
93. Rasch MG, Lund IK, Almasi CE, Høyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci 2008; 13: 6752-62.
94. Bianchi E, Cohen RL, Thor AT, et al. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994; 54: 861-6.
95. Nielsen BS, Rank F, Illemann M, Lund LR, Danø K. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int J Cancer 2007; 120: 2086-95.
96. Kotzsch M, Bernt K, Friedrich K, et al. Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma. Histopathology 2010; 57: 461-71.
97. Nielsen BS, Sehested M, Timshel S, Pyke C, Danø K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 1996; 74: 168-77.
98. Borgfeldt C, Hansson SR, Gustavsson B, Masbäck A, Asslén B. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int J Cancer 2001; 92: 497-502.
99. Usher PA, Thomsen OF, Iversen P, et al. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer 2005; 113: 870-80.
100. Pyke C, Ralfkiær E, Rønne E, Høyer-Hansen G, Kirkeby L, Danø K. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 1994; 24: 131-8.
101. Ohtani H, Pyke C, Danø K, Nagura H. Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis. Int J Cancer 1995; 62: 691-6.
102. Buø L, Meling GI, Karlsrud TS, Johansen HT, Aasen AO. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum Pathol 1995; 26: 1133-8.
103. Pyke C, Salo S, Ralfkiær E, Rømer J, Danø K, Tryggvason K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res 1995; 55: 4132-9.
104. Lenander C, Habermann JK, Ost A, et al. Laminin-5 gamma 2 chain expression correlates with unfavorable prognosis in colon carcinomas. Anal Cell Pathol 2001; 22: 201-9.
105. Skyldberg B, Salo S, Eriksson E, et al. Laminin-5 as a marker of invasiveness in cervical lesions. J Natl Cancer Inst 1999; 91: 1882-7.
106. Koretz K, Möller P, Schwartz-Albiez R. Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells. Eur J Cancer 1993; 29A: 1184-9.
107. Buø L, Lyberg T, Jørgensen L, Johansen HT, Aasen AO. Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas. APMIS 1993; 101: 235-41.
108. Harvey S, Kohga S, Sait SN, et al. Co-expression of urokinase with haptoglobin in human carcinomas. J Surg Res 2009; 152: 189-97.
109. Harvey SR, Sait SN, Xu Y, Bailey JL, Penetrante RM, Markus G. Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization. Am J Pathol 1999; 155: 1115-20.
110. Akahane T, Ishii M, Ohtani H, Nagura H, Toyota T. Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer. Liver 1998; 18: 414-9.
111. Dubuisson L, Monvoisin A, Nielsen BS, Le Bail B, Bioulac-Sage P, Rosenbaum J. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. J Pathol 2000; 190: 190-5.
112. Maeda T, Kajiyama K, Adachi E, Takenaka K, Sugimachi K, Tsuneyoshi M. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver. Mod Pathol 1996; 9: 901-9.
113. Rømer J, Pyke C, Lund LR, Ralfkiær E, Danø K. Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin. J Invest Dermatol 2001; 116: 353-8.
114. Ferrier CM, van Geloof WL, Straatman H, Van De Molengraft FJ, van Muijen GN, Ruiter DJ. Spitz naevi may express components of the plasminogen activation system. J Pathol 2002; 198: 92-9.
115. Larsson LI, Skriver L, Nielsen LS, Grøndahl-Hansen J, Kristensen P, Danø K. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol 1984; 98: 894-903.
116. Lund LR, Rømer J, Thomasset N, et al. Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development 1996; 122: 181-93.
117. Solberg H, Ploug M, Høyer-Hansen G, Nielsen BS, Lund LR. The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem 2001; 49: 237-46.
118. Almholt K, Green KA, Juncker-Jensen A, Nielsen BS, Lund LR, Rømer J. Extracellular Proteolysis in Transgenic Mouse Models of Breast Cancer. J Mammary Gland Biol Neoplasia 2007; 12: 83-97.
119. Rømer J, Lund LR, Eriksen J, et al. Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J Invest Dermatol 1991; 97: 803-11.
120. Rømer J, Lund LR, Eriksen J, Pyke C, Kristensen P, Danø K. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J Invest Dermatol 1994; 102: 519-22.
121. Grøndahl-Hansen J, Lund LR, Ralfkiær E, Ottevanger V, Danø K. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J Invest Dermatol 1988; 90: 790-5.
122. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993; 90: 5021-5.
123. Ignar DM, Andrews JL, Witherspoon SM, et al. Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin Exp Metastasis 1998; 16: 9-20.
124. Hu XW, Duan HF, Gao LH, et al. Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor. Cancer Biol Ther 2008; 7: 651-9.
125. Min HY, Doyle LV, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996; 56: 2428-33.
126. Tressler RJ, Pitot PA, Stratton JR, et al. Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth. APMIS 1999; 107: 168-73.
127. Bauer TW, Liu W, Fan F, et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor- mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 2005; 65: 7775-81.
128. Van Buren G, Gray MJ, Dallas NA, et al. Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer 2009; 115: 3360-8.
129. http://www.tacticpharma.com/ATN-658.html. [Cited 04.02.2011].
130. Kriegbaum M, Persson M, Haldager L, et al. Rational targeting of the urokinase receptor (uPAR): Development of inhibitors and non-invasive imaging probes. Curr Drug Targets 2011; 12: 1711-28.
131. Pass J, Jögi A, Lund IK, et al. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: Inhibitory effects on receptor-mediated uPA activity in vitro and in vivo. Thromb Haemost 2007; 97: 1013-22.
132. Pass J, Gårdsvoll H, Lund LR, Danø K, Høyer-Hansen G. Generation of antibodies to the urokinase receptor (uPAR) by DNA immunization of uPAR knockout mice: membrane-bound uPAR is not required for an antibody response. Scand J Immunol 2003; 58: 298-305.
133. Rasch MG, Pass J, Illemann M, Høyer-Hansen G, Lund IK. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies. J Immunol Methods 2008; 339: 55-65.
134. Jögi A, Pass J, Høyer-Hansen G, et al. Systemic administration of anti-urokinase plasminogen activator receptor monoclonal antibodies induces hepatic fibrin deposition in tissue-type plasminogen activator deficient mice. J Thromb Haemost 2007; 5: 1936-44.
135. Shapiro RL, Duquette JG, Roses DF, et al. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA- deficient animals. Cancer Res 1996; 56: 3597-604.
136. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000; 60: 5839-47.
137. Almholt K, Lund LR, Rygaard J, et al. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 2005; 113: 525-32.
138. Høyer-Hansen G, Ploug M, Behrendt N, Rønne E, Danø K. Cell- surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 1997; 243: 21-6.
139. Ngo JCK, Jiang L, Lin Z, et al. Structural basis for therapeutical intervention of uPA/uPAR system. Curr Drug Targets 2011; 12: 1729-43.
140. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983; 35: 611-9.
141. Hearing VJ, Law LW, Corti A, Appella E, Blasi F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 1988; 48: 1270-8.
142. Ossowski L, Russo-Payne H, Wilson EL. Inhibition of urokinase- type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 1991; 51: 274-81.
143. Kobayashi H, Gotoh J, Shinohara H, Moniwa N, Terao T. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb Haemost 1994; 71: 474-80.
144. Lund IK, Jögi A, Rønø B, et al. Antibody-mediated targeting of the urokinase-type plasminogen activator proteolytic function neutralizes fibrinolysis in vivo. J Biol Chem 2008; 283: 32506-15.
145. Jögi A, Rønø B, Lund IK, et al. Neutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient mice. PLoS ONE 2010; 5: e12746.
146. Blouse GE, Bøtkjær KA, Deryugina E, et al. A novel mode of intervention with serine protease activity: targeting zymogen activation. J Biol Chem 2009; 284: 4647-57.
147. Conn EM, Bøtkjær KA, Kupriyanova TA, Andreasen PA, Deryugina EI, Quigley JP. Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion. Am J Pathol 2009; 175: 1638-52.
148. Sgier D, Zuberbuehler K, Pfaffen S, Neri D. Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA. Protein Eng Des Sel 2010; [epub ahead of print].
149. Bugge TH, Lund LR, Kombrinck KK, et al. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998; 16: 3097-104.
150. Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 2001; 276: 17976-84.
151. Liu S, Aaronson H, Mitola DJ, Leppla SH, Bugge TH. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci USA 2003; 100: 657-62.
152. Su Y, Ortiz J, Liu S, et al. Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non- small cell lung tumor in athymic nude mice. Cancer Res 2007; 67: 3329-36.
153. Biethahn S, Alves F, Wilde S, Hiddemann W, Spiekermann K. Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Exp Hematol 1999; 27: 885-94.
154. Abi-Habib RJ, Liu S, Bugge TH, Leppla SH, Frankel AE. A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts. Blood 2004; 104: 2143-8.
155. Liu S, Redeye V, Kuremsky JG, et al. Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin. Nat Biotechnol 2005; 23: 725-30.
156. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60: 636-43.
157. Kotzsch M, Luther T, Harbeck N, et al. New ELISA for quantitation of human urokinase receptor (CD87) in cancer. Int J Oncol 2000; 17: 827-34.
158. Werle B, Kotzsch M, Lah TT, et al. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator- receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 2004; 24: 4147-61.
159. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999; 39: 123-9.
160. Riisbro R, Christensen IJ, Nielsen HJ, Brünner N, Nilbert M, Fernebro E. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration. Int J Biol Markers 2005; 20: 93-102.
161. Pyke C, Kristensen P, Ralfkiær E, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991; 138: 1059-67.